Exosomal microRNA as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Kohli, Manish
Huang, Xiaoyi
Yuan, Tiezheng
Sun, Zhifu
Costello, Brian Addis
Quevedo, Fernando
Tan, Winston
Nandy, Debashis
Longenbach, Sherri
Wang, Liang
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[3] Mayo Clin, Jacksonville, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.260
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
260
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Karnes, R. Jeffrey
    Ahmed, Mohamed E.
    APPLIED RADIOLOGY, 2021, 50 (01) : 42 - 43
  • [2] Analysis of the prognostic significance of circulating tumor DNA (ctDNA) in metastatic castrate-resistant prostate cancer (mCRPC)
    Shaya, Justin
    Randall, James Michael
    Millard, Frederick E.
    Kurzrock, Razelle
    Parsons, J. Kellogg
    Tamayo, Pablo
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Impact of comorbidity on outcome in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Zist, A.
    Amir, E.
    Ocana, A.
    Seruga, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S703 - S703
  • [4] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [5] Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
    Moses, Marcus Marie
    Ledet, Elisa
    Manogue, Charlotte
    Lewis, Brian E.
    Barata, Pedro C.
    Sartor, A. Oliver
    Layton, Jodi Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [6] Metastatic castrate-resistant prostate cancer
    Schellhammer, Paul
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (01) : 51 - 52
  • [7] Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).
    Ravi, Praful Kumar
    Mateo, Joaquin
    Zafeiriou, Zafeiris
    Altavilla, Amelia
    Ferraldeschi, Roberta
    Sideris, Spyridon
    Grist, Emily
    Smith, Alan D.
    Wong, Sophia
    Lorente, David Look
    Bianchini, Diletta
    Attard, Gerhardt
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Prognostic factors for patients with metastatic castrate-resistant prostate cancer (mCRPC) receiving abiraterone acetate prechemotherapy.
    Charnley, Natalie
    Birtle, Alison J.
    Swindell, Ric
    Parikh, Omi
    Wise, Marcus
    Kumar, Varadarajan
    Danwata, Falalu Dahiru
    Thompson, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
    Thomson, Alastair
    Pollard, Adam
    Mark, Frances May
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] Olaparib in metastatic castrate-resistant prostate cancer
    不详
    BJU INTERNATIONAL, 2020, 126 (02) : 235 - 235
12345